The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells in patients with early type 1 diabetes.

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its ...

The Toronto Blue Jays have been off to a slow start this season but one player that has been at the top of his game since the start of Spring Training has been Bo Bichette. The Blue Jays have had a ...

The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference ...

Denosumab-bnht (Conexxence/Bomyntra, Fresenius Kabi) received FDA approval based on findings from two comparative clinical studies. One study assessed the pharmacokinetics, pharmacodynamics and ...

As the sun warms up the season, it’s time to refresh your wardrobe with breezy silhouettes and styles that make you feel cool while looking hot. Whether you’re drawn to pastel hues, sharp tailoring, ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht) of ...

March 27, 2025--(BUSINESS WIRE)--Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht ...

Fresenius’ operating company Fresenius Kabi reached a global settlement with Amgen concerning their denosumab biosimilars, allowing launch in the U.S. in mid-2025 and in Europe later in H2 of ...

Bo Nickal and Dylan Palacio recently indulged in an online feud over their commitment to wrestling. Nickal accused a Penn State University wrestler of indulging in unethical practices. "It was ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news ...